deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 4-arm NCT03074318

Avelumab and Trabectedin in Treating Patients With Liposarcoma or Leiomyosarcoma That is Metastatic or Cannot Be Removed by Surgery

A Phase I/II Trial Combining Avelumab and Trabectedin for Advanced Liposarcoma and Leiomyosarcoma

Sponsor: EMD Serono

Conditions Metastatic Leiomyosarcoma Metastatic Liposarcoma Unresectable Leiomyosarcoma Unresectable Liposarcoma
Interventions Avelumab Trabectedin
Updated 18 times since 2017 Last updated: Apr 27, 2022 Started: Sep 28, 2017 Primary completion: Nov 15, 2020 Completion: Nov 15, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Terminated due to PI leaving institution

Other terminated trials from EMD Serono

See all terminations from EMD Serono

Listed as NCT03074318, this PHASE1/PHASE2 trial focuses on Metastatic Leiomyosarcoma and Metastatic Liposarcoma and remains terminated or withdrawn. Sponsored by EMD Serono, it has been updated 18 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~May 2017 – ~Oct 2017 · 5 months · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jun 2018 · 6 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Mar 2019 · 8 months · monthly snapshot~Mar 2019 – ~May 2019 · 2 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Aug 2019 · 31 days · monthly snapshot~Aug 2019 – ~Mar 2020 · 7 months · monthly snapshot~Mar 2020 – ~Apr 2020 · 31 days · monthly snapshot~Apr 2020 – ~Nov 2020 · 7 months · monthly snapshot~Nov 2020 – ~Dec 2020 · 30 days · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~May 2022 · 16 months · monthly snapshot~May 2022 – ~Jul 2024 · 26 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  3. May 2022 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

  4. Jan 2021 — May 2022 [monthly]

    Terminated PHASE1_PHASE2

  5. Dec 2020 — Jan 2021 [monthly]

    Terminated PHASE1_PHASE2

    Status: Active Not Recruiting → Terminated

▶ Show 13 earlier versions

  1. Nov 2020 — Dec 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Apr 2020 — Nov 2020 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Mar 2020 — Apr 2020 [monthly]

    Recruiting PHASE1_PHASE2

  4. Aug 2019 — Mar 2020 [monthly]

    Recruiting PHASE1_PHASE2

  5. Jul 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Suspended → Recruiting

  6. Jun 2019 — Jul 2019 [monthly]

    Suspended PHASE1_PHASE2

  7. May 2019 — Jun 2019 [monthly]

    Suspended PHASE1_PHASE2

  8. Mar 2019 — May 2019 [monthly]

    Suspended PHASE1_PHASE2

    Status: Recruiting → Suspended

  9. Jul 2018 — Mar 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1_PHASE2

  11. Dec 2017 — Jun 2018 [monthly]

    Recruiting PHASE1_PHASE2

  12. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. May 2017 — Oct 2017 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • EMD Serono
  • Fred Hutchinson Cancer Center
  • National Cancer Institute (NCI)
Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations